Cancer

News

AZ's immunotherapy combo misses the mark in untreated lung c...

AstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival compared with standard chemotherapy in a phase 3 tria

Views & Analysis

NICE’s track record in cancer drugs: the impact of the CDF a...

Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.

News

FDA approves Roche's "tumour agnostic" drug Rozlytrek

The FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in cancer, instead of where the disease originates. <

News

Janssen J&J Johnson and Johnson pharmaceutical companies

AbbVie/Janssen win EU approval for two new Imbruvica uses

European regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of the blood cancer drug.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer jumps on KRAS cancer drug bandwagon with MD Ander...

Boehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, striking a multi-year oncology research deal with the University of Tex

News

AZ's lung cancer drug Tagrisso gets boost from first line OS...

AstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung cancer with certain mutations, compared with older alt

AZ's immunotherapy combo misses the mark in untreated lung c...

NICE’s track record in cancer drugs: the impact of the CDF a...

FDA approves Roche's "tumour agnostic" drug Rozlytrek

AbbVie/Janssen win EU approval for two new Imbruvica uses

Boehringer jumps on KRAS cancer drug bandwagon with MD Ander...

AZ's lung cancer drug Tagrisso gets boost from first line OS...

Amgen's Horizon buyout delivers Sjögren's disease win

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks